Bezwoda 1986.

Methods	Randomised Phase II trial 1982 to 1984
Participants	50 women with recurrent or metastatic cervical cancer
Interventions	Arm 1: hydroxyurea 1.5 g/m2 po d1‐10, 14‐d rest period then maintenance with 1 g/m2 po d1‐14 q28 Arm 2: cisplatin 20 mg/m2 iv daily d1‐3 and methotrexate 100 mg/m2 iv d3 with leucovorin rescue
Outcomes	OS Response rates Toxicity
Notes	3 patients were excluded (refused chemotherapy after randomisation). No ITT analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not documented
Allocation concealment (selection bias)	Unclear risk	Not documented
Blinding (performance bias and detection bias) All outcomes	Low risk	Not documented but OS unlikely to be affected by blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	3 patients were excluded
Selective reporting (reporting bias)	Low risk	Published report included all pre‐specified outcomes
Other bias	High risk	Hydroxyurea (arm 1) arm stopped early owing to lack of response, only 12 patients randomised to cisplatin + methotrexate arm (arm 2), the remainder entered that arm as only treatment option once the hydroxyurea arm closed. Thus many randomised and trial results not used in meta‐analyses